PRVB - Why This Under-the-Radar Biotech Stock Could Skyrocket
Investing in clinical-stage biotech stocks is risky. While positive results from clinical trials can send shares flying, the probability of a newly developed drug successfully making its way through all phases of the clinical trial process and earning regulatory approval is low. Still, picking the right biotech stock early enough can prove highly lucrative in the long run.
With that in mind, here's one biotech stock I think investors would do well to keep an eye on: Provention Bio (NASDAQ: PRVB). This company has performed more or less in line with the broader market year to date, and it could have a bright future.